Geovax Labs Inc. (GOVX)
NASDAQ (CM) NASDAQ (CM) Primary 
GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
GeoVax Labs (GOVX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript
GeoVax Labs, Inc. ( GOVX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants David Dodd - Chairman, President & CEO Mark Reynolds - CFO & Corporate Secretary John Sharkey - Vice President of Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Laura Suriel John Vandermosten - Zacks Investment Research, Inc. Presentation Operator Good afternoon, and welcome, everyone, to the GeoVax Third Quarter 2025 Corporate Update Call. My name is Sherry, and I will facilitate today's call.
GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company Participants David Alan Dodd - Chairman, President & CEO John W. Sharkey - Vice President of Business Development Kelly T.
GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Max Gadicke - Precision AQ, Investor Relations David Dodd - Chairman, President & Chief Executive Officer Mark Reynolds - Chief Financial Officer Conference Call Participants James Molloy - Alliance Global Partners Robert LeBoyer - Noble Capital Markets Jeffrey Kraws - Crystal Research Associates Operator Good afternoon. And welcome everyone to the GeoVax First Quarter 2025 Corporate Update Call.
GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript
GeoVax Labs, Inc. (NASDAQ:GOVX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Max Gadicke - Precision AQ, Investor Relations David Dodd - Chairman, President & CEO Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Robert LeBoyer - Noble Capital Markets Laura Suriel - Alliance Global Partners Operator Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call.
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?
After reaching an important support level, GeoVax Labs Inc. (GOVX) could be a good stock pick from a technical perspective. GOVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
GeoVax Labs NASDAQ: GOVX is currently a micro-cap biotech stock that multiple Wall Street analysts see massive potential appreciation in. Working on a treatment for a disease that the World Health Organization (WHO) just declared a “public health emergency," investors should be informed about the company.
GeoVax's stock slides 20% after company raises $8.5 million in stock sale
GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale of 1.7 million shares priced at $5 each in a registered direct offering. The stock closed Monday up 1.7% at $7.15, after a rollercoaster session that saw it soar more than 40% at its peak, on excitement about its work to develop an mpox vaccine.
GeoVax's stock soars 54% to lead rally in companies developing mpox treatments
GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet its main goal.
